STOCK COMPARISON
Lumi vs Fredun Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Lumi (LUMI) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 8, 2026.
As of Aug 8, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the less overvalued of the two: Lumi trades at NOK 18.20 versus a fair value of NOK 10.93 (-40%), while Fredun Pharmaceuticals trades at ₹2,589 versus ₹2,155 (-17%).
Lumi
LUMI.OL · NOK · Consumer Discretionary
-40%
upside to fair value
overvalued
PriceNOK 18.20
Fair ValueNOK 10.93
Quality53/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
-17%
upside to fair value
overvalued
Price₹2,589
Fair Value₹2,155
Quality50/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
LumiFredun Pharmaceuticals
Valuation
37.6×P/E (TTM)42.2×
2.15×P/S (TTM)2.23×
2.09×P/B5.03×
13.8×EV/EBITDA15.5×
—Dividend yield0.0%
—Dividend per share₹0.70
Profitability
6%Net margin5%
16%Operating margin12%
6%Return on equity16%
4%Return on assets9%
Growth
14%Revenue growth (YoY)27%
-0.4%Avg. growth/yr (3Y)32.2%
-0.5%Avg. growth/yr (5Y)36.9%
Balance & size
—Debt / equity0.20×
$114MMarket cap$149M
weakGrowth qualityexpensive
Lumi leads: 6 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Lumiof which business quality 51 · market factors 52
Fredun Pharmaceuticalsof which business quality 35 · market factors 85
ProfitabilityMargins and returns on capital today
30
48
Quality GrowthAre margins and returns improving?
61
73
CashflowEarnings quality: real cash, not paper profit
65
5
Fin. StrengthBalance sheet, leverage, solvency risk
38
57
InvestmentDisciplined investing over empire-building
98
16
Low VolatilityCalm price path (market factor)
78
56
MomentumPrice trend over the last 3–12 months (market factor)
40
100
52W MomentumDistance to the 52-week high (market factor)
43
93
Net IssuanceBuybacks instead of dilution
32
7
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Lumi
DCF ModelsNOK 12.56
Earnings-BasedNOK 7.60
MultiplesNOK 13.33
Asset-BasedNOK 6.03
Growth DCFNOK 12.19
Economic ProfitNOK 8.87
Growth EarningsNOK 7.99
20 of 23 models see the stock below the current price.
Fredun Pharmaceuticals
Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535
11 of 14 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Lumi
Bear NOK 8.14Fair Value NOK 10.93Bull NOK 13.67
NOK 18.20 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,509Fair Value ₹2,155Bull ₹2,802
₹2,589 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Lumi · Consumer Discretionary
Quality score53 · above median
Fair value upside-40% · below median
Fredun Pharmaceuticals · Healthcare
Quality score50 · above median
Fair value upside-17% · above median
Bottom line
As of Aug 8, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the less overvalued of the two: Lumi trades at NOK 18.20 versus a fair value of NOK 10.93 (-40%), while Fredun Pharmaceuticals trades at ₹2,589 versus ₹2,155 (-17%).
Lumi has the higher quality score (53/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
